AITX's RAD Receives RIO(TM) Expansion Orders from Major Client
Detroit, Michigan--(Newsfile Corp. - June 2, 2025) - Artificial Intelligence Technology Solutions, Inc. (OTC Pink: AITX) (the 'Company'), a global leader in AI-driven security and productivity solutions for enterprise clients, along with its wholly owned subsidiary Robotic Assistance Devices, Inc. (RAD), today announced that a major global logistics client has placed additional orders for multiple RIO 360 solar-powered security towers, each equipped with SARA ™ (Speaking Autonomous Responsive Agent), AITX's proprietary Agentic AI platform. These new deployments on the West Coast represent a continuation of the client's ongoing national expansion of RAD's security technology and software.
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/5243/254111_aitx-rad-rio-order-from-large-client-250602-1920x1080_550.jpg ]
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/5243/254111_aitx-rad-rio-order-from-large-client-250602-1920x1080.jpg
Artist's depiction of a RAD RIO 360 solar tower positioned outside a large distribution center.
This latest order underscores the growing confidence major organizations have in RAD's solutions to address evolving security challenges at scale. By extending their deployment of RIO units across additional facilities, the client demonstrates a commitment to leveraging advanced AI and automation for greater site protection, operational efficiency, and standardized incident response nationwide.
The RIO 360 units will be deployed at the client's distribution and logistics centers, where they serve as a reliable and cost-effective alternative to traditional manned security posts. Each unit is connected to SARA in the cloud, enabling real-time intelligent monitoring, automated voice talk-downs to deter suspicious activity, immediate notifications to security personnel, and comprehensive incident reporting. This seamless integration allows the RIO units to deliver consistent site monitoring and rapid response, helping the client strengthen facility security while optimizing operational resources.
'We are proud to support this client's nationwide growth with solutions that deliver proven results in challenging environments,' said Mark Folmer, CPP, PSP, President of RAD. 'Their continued adoption of RIO and SARA highlights the value and impact that AI-driven security can bring to complex logistics operations. We look forward to helping more organizations realize similar benefits as they modernize their security strategies.'
SARA's growing adoption across a variety of industries and sectors reflects a broader shift toward AI-powered, autonomous security solutions. With each new deployment, SARA further establishes its role as an essential technology for organizations seeking to automate routine monitoring, accelerate incident response, and maintain consistency across multiple sites. The momentum seen in this rollout signals increasing demand for intelligent security platforms that deliver reliable performance in real-world environments.
Sitting atop a standard RIO 360 configuration are dual ROSA™ units. ROSA is a multiple award-winning, compact, self-contained, portable, security and communication solution that can be installed and activated in about 15 minutes. ROSA's AI-driven security analytics include human, firearm, vehicle detection, license plate recognition, responsive digital signage and audio messaging, and complete integration with RAD's software suite notification and autonomous response library. Two-way communication is optimized for cellular, including live video from ROSA's high-resolution, full-color, always-on cameras. RAD has published six Case Studies detailing how ROSA has helped eliminate instances of theft, trespassing and loitering at retail centers, hospital campuses, multi-family communities, car rental locations and construction sites across the country.
AITX, through its subsidiary, Robotic Assistance Devices, Inc. (RAD), is redefining the nearly $50 billion (US) security and guarding services industry 1 through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide cost savings to businesses of between 35%-80% when compared to the industry's existing and costly manned security guarding and monitoring model. RAD delivers these tremendous cost savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house.
The Company's operations and internal controls have been validated through successful completion of its SOC 2 Type 2 audit, reinforcing the Company's credibility with enterprise and government clients who require strict data protection and security compliance.
RAD has a prospective sales pipeline of over 35 Fortune 500 companies and numerous other client opportunities. RAD expects to continue to attract new business as it converts its existing sales opportunities into deployed clients generating a recurring revenue stream. Each Fortune 500 client has the potential of making numerous reorders over time.
About Artificial Intelligence Technology Solutions (AITX)
AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX's RAD, RAD-R, RAD-M and RAD-G companies help organizations streamline operations, increase ROI, and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staff and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education, and healthcare. To learn more, visit www.aitx.ai, www.radsecurity.com, www.stevereinharz.com, www.radgroup.ai, www.raddog.ai, and www.radlightmyway.com, or follow Steve Reinharz on X @SteveReinharz.
CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS
The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Artificial Intelligence Technology Solutions, Inc. (the 'Company'). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.
###
Steve Reinharz
949-636-7060
@SteveReinharz
1 https://www.ibisworld.com/united-states/market-research-reports/security-services-industry/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254111
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
17 minutes ago
- Business Wire
Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new drug applications (INDs) for its lead candidate, Entolimod™. The two INDs cover the use of Entolimod to treat acute radiation syndrome, including both hematopoietic (ARS-H) and gastrointestinal (ARS-GI) sub-syndromes, and the use of Entolimod to treat advanced cancers, including as an anti-tumor agent and for conditions resulting from cancer treatments. 'Transfer of these INDs to Tivic allows us to formally engage the FDA regarding Entolimod's regulatory pathway and enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-related conditions,' stated Tivic CEO, Jennifer Ernst. 'While the IND for advanced cancers allows exploration of Entolimod's anti-tumor activity, building on prior developments, we remain focused in the near-term on Entolimod's first indication--acute radiation syndrome.' About Entolimod Entolimod is a novel TLR5 agonist that triggers NF-kB signaling, activating antiapoptotic and cell protective mechanisms. Under the FDA's Animal Rule, Entolimod has been the subject of extensive trials for the treatment of acute radiation syndrome (ARS), and has demonstrated robust survival, enhanced GI tract recovery and improved hematopoiesis in animal models. Entolimod has been granted Fast Track Designation for ARS. Tivic also holds the exclusive rights for Entolimod for the treatment of neutropenia and has the option to license additional indications, including lymphocyte exhaustion, immunosenescence, and chronic radiation syndrome. About Tivic Tivic's dual platform strategy utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late-stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; timing and success of clinical trials and study results; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; regulatory requirements and pathways for approval; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors,' as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
Business Wire
an hour ago
- Business Wire
ClearStrand-ASD, First-of-Its-Kind Autism Screening Tool, Now Available in Japan
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- LinusBio, a leader in precision exposome medicine, announced today that ClearStrand-ASD™, its biochemical autism screening test, is now available to patients and providers in Japan for research use through its partnership with YAC Bio. This milestone marks LinusBio's first international expansion and represents a significant step in the company's mission to enable earlier identification of autism spectrum disorder (ASD) globally. Today marks a transformational moment in our mission to make early autism screening accessible worldwide. Share ClearStrand-ASD requires only a strand of hair to detect molecular signatures associated with autism spectrum disorder. This innovative, non-invasive approach provides healthcare providers with an objective screening method that can help identify ASD risk as early as one month of age, allowing families to pursue intervention during the most crucial period of early development. "Today marks a transformational moment in our mission to make early autism screening accessible worldwide," said Dr. Manish Arora, Founder and CEO of LinusBio. "Japan represents our first step beyond U.S. borders, and we chose this market because of its sophisticated healthcare infrastructure and commitment to pediatric developmental care. Japanese families dealing with autism concerns will now have access to the same cutting-edge screening technology that has already helped multiple American families get answers earlier than ever before." The Japanese launch builds on ClearStrand-ASD's successful rollout across the United States, where it is now available in 49 states. YAC Bio will partner with hospital systems in Japan to facilitate the implementation of this first-of-its-kind biomarker test for autism. LinusBio's expansion into Japan is facilitated through its existing partnership with YAC Bio (part of Y.A.C. Holdings), the Japanese multinational that invested over 1 billion yen in the company. Beyond providing market access, Y.A.C. Holdings contributes manufacturing expertise and automation capabilities that support LinusBio's scaling efforts globally. "By combining the world's only hair-cutting robotics technology with the innovative hair exposome analysis developed by LinusBio in the United States, we have contributed to the development of the world's first biomarker screening test for autism spectrum disorder. Following its launch in the U.S., we are now offering this test in Japan through our group company, YAC Bio," said Takefumi Momose, President and CEO, Y.A.C. Holdings Co., Ltd. "We sincerely hope that this test will support individuals, families, and communities in Japan who are concerned about autism." The Japan availability of ClearStrand-ASD represents the first phase of LinusBio's international expansion strategy, with the company evaluating additional markets where ClearStrand-ASD could address unmet needs in early autism detection. About ClearStrand-ASD ClearStrand-ASD is a biochemical test intended to help health care providers rule out autism spectrum disorder (ASD) in children 1 to 48 months. The test analyzes a strand of hair to map the dynamic patterns of an individual's unique biological responses at a molecular level to environmental exposures over time and uses an algorithm to assess the likelihood of autism. It is not a genetic test and must be ordered by a licensed health care provider (Rx only). ClearStrand-ASD is performed at LinusBio's CLIA-certified laboratory (CLIA #31d2307499). For more information visit: About LinusBio LinusBio (Linus Biotechnology Inc.) is a patient-centric, breakthrough science precision exposome medicine company headquartered in New Jersey. The Company's program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology. LinusBio is actively exploring additional international partnerships to expand global access to its innovative diagnostic solutions. For more information, visit About Y.A.C. Holdings Y.A.C. Holdings is a Japan-based company specializing in developing, designing, and manufacturing mechatronics-related products. The company collaborates with LinusBio on hardware innovations to scale testing capacity, driving breakthroughs in robotics and laboratory automation.
Business Wire
an hour ago
- Business Wire
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse
NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse ™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume. 'This submission represents an important milestone in expanding our Evolysse ™ collection of injectable HA gels,' said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D. 'Sculpt is our most structured product, manufactured using a novel technology and designed to address mid-face volume loss, a high-value segment in facial aesthetics.' Evolus anticipates that the FDA's review will follow the standard PMA process, with approval expected in the second half of 2026. The submission underscores Evolus' commitment to bringing its collection of injectable hyaluronic acid gel products to market and its readiness to meet rigorous regulatory requirements. In support of the PMA application, a U.S. pivotal study which evaluated the safety and effectiveness of the product in a multicenter, double-blinded, controlled, non-inferiority designed trial was conducted. Patients were followed for 24 months from initial treatment. A total of 304 patients were enrolled and randomized to receive Evolysse ™ Sculpt or Restylane ® -Lyft. The Evolysse ™ Sculpt injectable HA gel product is expected to be the flagship brand in the Evolysse ™ collection. Designed by Symatese using innovative Cold-X ™ technology, which helps preserve the natural structure of the HA molecule for long-lasting, natural-looking results, Sculpt will enter the highest value segment for today's dermal filler market and be among the few products currently indicated for the mid-face area. About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse ™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at and follow us on LinkedIn, X, Instagram or Facebook. Forward-Looking Statements This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' or the negative of those terms, or other comparable terms intended to identify statements about the future. The company's forward-looking statements include, but are not limited to, statements related to anticipated product launches and the timing of regulatory submissions and approvals. The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to, uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, unfavorable global economic conditions and the impact on consumer discretionary spending, uncertainties related to customer and consumer adoption of Jeuveau ® and Evolysse ™, the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, including the Evolysse ™ dermal filler product line in the U.S., our ability to maintain regulatory approvals of Jeuveau ® or obtain regulatory approvals for new product candidates or indications, our reliance on Symatese to achieve regulatory approval for the Evolysse ™ dermal filler product line in the U.S., and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled 'Risk Factors' in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the Securities and Exchange Commission on August 5, 2025. These filings can be accessed online at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If we do update or revise one or more of these statements, investors and others should not conclude that we will make additional updates or corrections. Jeuveau ® and Nuceiva ®, are registered trademarks and Evolysse ™ is a trademark of Evolus, Inc. Hi-Pure ™ is a trademark of Daewoong Pharmaceutical Co, Ltd. Cold-X ™ and Estyme ® are trademarks of Symatese Group and Symatese Aesthetics S.A.S. Restylane ® is a trademark of Galderma S.A.
